

Xue-Qun Luo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1664276/publications.pdf>

Version: 2024-02-01

39
papers

1,161
citations

430874

18
h-index

395702

33
g-index

50
all docs

50
docs citations

50
times ranked

2114
citing authors

#	ARTICLE	IF	CITATIONS
1	The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway. <i>Cell Death and Differentiation</i> , 2017, 24, 212-224.	11.2	180
2	circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression. <i>Blood</i> , 2019, 134, 1533-1546.	1.4	142
3	LncRNA ANRIL regulates AML development through modulating the glucose metabolism pathway of AdipoR1/AMPK/SIRT1. <i>Molecular Cancer</i> , 2018, 17, 127.	19.2	112
4	MIR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 172, 62-68.	2.5	54
5	MIR-708 promotes phagocytosis to eradicate T-ALL cells by targeting CD47. <i>Molecular Cancer</i> , 2018, 17, 12.	19.2	53
6	circRNA circAF4 functions as an oncogene to regulate MLL-AF4 fusion protein expression and inhibit MLL leukemia progression. <i>Journal of Hematology and Oncology</i> , 2019, 12, 103.	17.0	53
7	A distinct set of long non-coding RNAs in childhood MLL-rearranged acute lymphoblastic leukemia: biology and epigenetic target. <i>Human Molecular Genetics</i> , 2014, 23, 3278-3288.	2.9	49
8	The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia. <i>Journal of Hematology and Oncology</i> , 2020, 13, 78.	17.0	47
9	Multicenter randomized trial of arsenic trioxide and Realgar<i>Indigo naturalis</i> formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG<i>APL clinical study. <i>American Journal of Hematology</i> , 2018, 93, 1467-1473.	4.1	44
10	Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 2795-2808.	7.0	33
11	The comparison of outcome and cost of three protocols for childhood non-high risk acute lymphoblastic leukemia in China. <i>Pediatric Blood and Cancer</i> , 2008, 51, 204-209.	1.5	31
12	Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways. <i>Leukemia and Lymphoma</i> , 2017, 58, 2426-2438.	1.3	30
13	High<i>risk childhood acute lymphoblastic leukemia in China: Factors influencing the treatment and outcome. <i>Pediatric Blood and Cancer</i> , 2009, 52, 191-195.	1.5	29
14	Maintenance therapy with dose<i>adjusted 6<i>mercaptopurine in idiopathic pulmonary hemosiderosis. <i>Pediatric Pulmonology</i> , 2008, 43, 1067-1071.	2.0	25
15	Butein inhibits cell proliferation and induces cell cycle arrest in acute lymphoblastic leukemia via FOXO3a/p27kip1 pathway. <i>Oncotarget</i> , 2016, 7, 18651-18664.	1.8	24
16	Melatonin inhibits MLL-rearranged leukemia via RbFOX3/hTERT and NF-<i>B/COX-2 signaling pathways. <i>Cancer Letters</i> , 2019, 443, 167-178.	7.2	22
17	Upregulation of the proto-oncogene Bmi-1 predicts a poor prognosis in pediatric acute lymphoblastic leukemia. <i>BMC Cancer</i> , 2017, 17, 76.	2.6	21
18	Nuclear export of chimeric mRNAs depends on an lncRNA-triggered autoregulatory loop in blood malignancies. <i>Cell Death and Disease</i> , 2020, 11, 566.	6.3	21

#	ARTICLE	IF	CITATIONS
19	Chromatin-associated orphan snoRNA regulates DNA damage-mediated differentiation via a non-canonical complex. <i>Cell Reports</i> , 2022, 38, 110421.	6.4	19
20	Cis-acting lnc-eRNA SEELA directly binds histone H4 to promote histone recognition and leukemia progression. <i>Genome Biology</i> , 2020, 21, 269.	8.8	17
21	Improved outcome for Chinese children with acute promyelocytic leukemia: A comparison of two protocols. <i>Pediatric Blood and Cancer</i> , 2009, 53, 325-328.	1.5	16
22	Functional Characteristics and Application of Mesenchymal Stem Cells in Systemic Lupus Erythematosus. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2021, 69, 7.	2.3	15
23	Flavokawain B inhibits the growth of acute lymphoblastic leukemia cells via p53 and caspase-dependent mechanisms. <i>Leukemia and Lymphoma</i> , 2015, 56, 2398-2407.	1.3	14
24	Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol. <i>BMC Cancer</i> , 2021, 21, 59.	2.6	14
25	Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD. <i>Leukemia and Lymphoma</i> , 2020, 61, 2692-2699.	1.3	12
26	High-Level Expression, Purification and Large-Scale Production of L-Methionine S-Methyltransferase from <i>Idiomarina</i> as a Novel Anti-Leukemic Drug. <i>Marine Drugs</i> , 2015, 13, 5492-5507.	4.6	10
27	Up-regulated miR-155 is associated with poor prognosis in childhood acute lymphoblastic leukemia and promotes cell proliferation targeting ZNF238. <i>Hematology</i> , 2021, 26, 16-25.	1.5	10
28	Prognostic Value and Outcome for ETV6/RUNX1-Positive Pediatric Acute Lymphoblastic Leukemia: A Report From the South China Children's Leukemia Group. <i>Frontiers in Oncology</i> , 2021, 11, 797194.	2.8	8
29	High-Dose Chemotherapy without Stem Cell Transplantation for Refractory Childhood Systemic Lupus Erythematosus. <i>Chemotherapy</i> , 2008, 54, 331-335.	1.6	7
30	A PROSPECTIVE STUDY OF FEBRILE EPISODES IN INPATIENT CHILDREN ON CHEMOTHERAPY. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 968-970.	2.0	7
31	MTHFR-C677T Gene Polymorphism and Susceptibility to Acute Lymphoblastic Leukemia in Children: A Meta-Analysis. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2020, 30, 125-136.	0.9	7
32	The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 45-52.	2.3	7
33	Five Chinese Pediatric Patients with Leukemias Possibly Arising from Immature Natural Killer Cells: Clinical Features and Courses. <i>Pediatric Hematology and Oncology</i> , 2011, 28, 187-193.	0.8	6
34	Retrospective analysis of 119 cases of pediatric acute promyelocytic leukemia: Comparisons of four treatment regimes. <i>Experimental and Therapeutic Medicine</i> , 2012, 4, 93-98.	1.8	6
35	Abnormal thymic B cell activation and impaired T cell differentiation in pristane-induced lupus mice. <i>Immunology Letters</i> , 2021, 231, 49-60.	2.5	5
36	Current status of diagnosis and prognosis of infant acute leukemia in China. <i>Pediatric Blood and Cancer</i> , 2009, 53, 973-977.	1.5	4

#	ARTICLE	IF	CITATIONS
37	A Nomogram for Predicting Event-Free Survival in Childhood Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , 2022, 12, 854798.	2.8	3
38	A CRISPR/CAS9-based strategy targets the personalized chimeric neosequence in fusion-driven cancer genome for precision medicine. <i>Clinical and Translational Medicine</i> , 2021, 11, e355.	4.0	2
39	Encephalopathy and brain atrophy during induction chemotherapy in acute lymphoblastic leukemia. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 1858-1859.	0.5	0